<DOC>
	<DOCNO>NCT00070174</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy donor bone marrow transplant help stop growth cancer cell . It also help stop patient 's immune system reject donor 's stem cell . Also , monoclonal antibody , gemtuzumab ozogamicin , find cancer cell either kill deliver cancer-killing substance without harm normal cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . PURPOSE : This phase II trial study well gemtuzumab ozogamicin work treat young patient undergoing remission induction , intensification therapy , allogeneic bone marrow transplant newly diagnose acute myeloid leukemia .</brief_summary>
	<brief_title>Gemtuzumab Ozogamicin Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction Intensification Therapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety gemtuzumab ozogamicin child newly diagnose acute myeloid leukemia undergo intensive remission induction intensification therapy . - Determine complete remission rate patient treat regimen . Secondary - Determine feasibility perform biological study ( e.g. , FLT3-ITD MRD ) risk group stratification patient . - Determine effect karyotypic abnormality survival patient treated regimen . OUTLINE : This multicenter study . - Induction I : Patients receive high-dose cytarabine ( ARA-C ) IV twice daily day 1-10 ; daunorubicin IV 6 hour day 1 , 3 , 5 ; etoposide IV 4 hour day 1-5 ; gemtuzumab ozogamicin IV 2 hour day 6 . Patients CNS-negative disease receive ARA-C intrathecally ( IT ) day 1 . Patients CNS-positive disease receive ARA-C IT twice weekly 2-3 week . Between day 28-35 , patient evaluate . Patients achieve remission 20 % blast proceed induction II . - Induction II : Patients receive ARA-C IV twice daily day 1-8 ; ARA-C IT day 1 ; daunorubicin IV etoposide IV induction I . Between day 28-35 patient evaluate . Patients achieve complete remission proceed intensification course I . - Intensification course I : Patients receive ARA-C IV 1 hour twice daily day 1-5 ; ARA-C IT induction II ; etoposide IV 1 hour day 1-5 . Patients evaluate day 28 . Patients 5/6 6/6 match family donor proceed allogeneic bone marrow transplantation . All patient complete remission proceed intensification course II . - Intensification course II : Patients receive ARA-C IV 2 hour twice daily day 1-4 ; ARA-C IT induction II ; mitoxantrone IV 1 hour day 3-6 ; gemtuzumab ozogamicin IV 2 hour day 7 . Patients evaluate day 28 proceed intensification course III . - Intensification course III : Patients receive ARA-C IV 3 hour twice daily day 1 , 2 , 8 , 9 asparaginase intramuscularly day 2 9 . - Allogeneic bone marrow transplantation : Patients receive preparative regimen comprise busulfan IV 2 hour 4 time daily day -9 -6 cyclophosphamide IV 1 hour daily day -5 -2 . Allogeneic stem cell infuse day 0 . - Graft-versus-host disease prophylaxis : Patients receive oral IV cyclosporine twice daily day -1 50 methotrexate IV daily day 1 , 3 , 6 , 11 . In course , treatment continue absence disease progression unacceptable toxicity . Patients follow monthly 6 month , every 2 month 6 month , every 4 month 1 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 330 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose primary acute myeloid leukemia ( AML ) At least 20 % bone marrow blast Meets customary FAB criterion AML Patients cytopenias bone marrow blast meet FAB criterion eligible provide karyotypic abnormality characteristic de novo AML ( e.g. , [ 8 ; 21 ] , inv16 , [ 16 ; 16 ] ) OR unequivocal presence megakaryoblasts Isolated granulocytic sarcoma ( myeloblastoma ) allow regardless result outline Previously untreated disease No promyelocytic leukemia ( FAB M3 ) No document myelodysplastic syndrome ( preleukemia ) ( e.g. , chronic myelomonocytic leukemia , refractory anemia [ RA ] , RA excess blast , RA ring sideroblast ) No juvenile myelomonocytic leukemia No Fanconi 's anemia , Kostmann syndrome , Shwachman syndrome , know bone marrow failure syndrome No Down syndrome PATIENT CHARACTERISTICS : Age 1 month 21 years* NOTE : *Children 1 month age progressive disease allow Performance status Karnofsky 50100 % ( 16 year age ) OR Lansky 50100 % ( age 1 16 ) * NOTE : Children 1 year age require performance status Life expectancy Not specify Hematopoietic Not specify Hepatic No inadequate liver function Renal No inadequate renal function No hyperuricemia ( great 8.0 mg/dL ) Creatinine clearance radioisotope glomerular filtration rate ( GFR ) least 70 mL/min OR equivalent normal GFR OR Creatinine great 1.5 time normal Cardiovascular Shortening fraction least 27 % echocardiogram OR Ejection fraction least 50 % MUGA Pulmonary No proven suspect pneumonia Other Not pregnant nursing No proven suspect sepsis meningitis PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy except intrathecal cytarabine administer administered diagnosis Endocrine therapy Prior topical inhalation steroid allow No concurrent steroid antiemetic Radiotherapy No prior radiotherapy Surgery Not specify Other No prior antileukemic therapy No concurrent pressor agent ventilatory support unless approve study chair No concurrent participation another COG therapeutic study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>childhood acute monocytic leukemia ( M5b )</keyword>
	<keyword>childhood acute megakaryocytic leukemia ( M7 )</keyword>
	<keyword>childhood acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>childhood acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>childhood acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>childhood acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>childhood acute monoblastic leukemia ( M5a )</keyword>
	<keyword>childhood acute erythroleukemia ( M6 )</keyword>
</DOC>